These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3096624)

  • 41. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.
    Kirch W; Rose I; Demers HG; Leopold G; Pabst J; Ohnhaus EE
    Clin Pharmacokinet; 1987 Aug; 13(2):110-7. PubMed ID: 2887325
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of ceftriaxone in subjects with renal insufficiency.
    Kowalsky SF; Echols RM; Parker MA
    Clin Pharm; 1985; 4(2):177-81. PubMed ID: 3987216
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Validity of creatinine clearance estimates in the assessment of renal function.
    Luke DR; Halstenson CE; Opsahl JA; Matzke GR
    Clin Pharmacol Ther; 1990 Nov; 48(5):503-8. PubMed ID: 2225710
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lead absorption and renal dysfunction in a South African battery factory.
    Ehrlich R; Robins T; Jordaan E; Miller S; Mbuli S; Selby P; Wynchank S; Cantrell A; De Broe M; D'Haese P; Todd A; Landrigan P
    Occup Environ Med; 1998 Jul; 55(7):453-60. PubMed ID: 9816378
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Case of lead nephropathy due to chronic occupational lead exposure].
    Ogata A; Sueta S; Tagawa M
    Nihon Jinzo Gakkai Shi; 2011; 53(2):207-11. PubMed ID: 21516708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function.
    Pearson JG; Antal EJ; Raehl CL; Gorsch HK; Craig WA; Albert KS; Welling PG
    Clin Pharmacol Ther; 1986 Mar; 39(3):318-24. PubMed ID: 3081293
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The pharmacology of cefamandole in patients with reduced renal function.
    Czerwinski AW; Pederson JA
    Scand J Infect Dis Suppl; 1980; suppl 25():45-8. PubMed ID: 6937951
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A pharmacokinetic study of roxatidine acetate in chronic renal failure.
    Lameire N; Rosenkranz B; Maass L; Brockmeier D
    Drugs; 1988; 35 Suppl 3():48-52. PubMed ID: 2905249
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biliary excretion of lead in rats drinking lead-containing water.
    Cikrt M; Lepsí P; Tichý M
    Toxicol Lett; 1983 Apr; 16(1-2):139-43. PubMed ID: 6404012
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma glutathione peroxidase activity in the elderly.
    Wieczorowska-Tobis K; Wisniewska J; Korybalska K; Polubinska A; Breborowicz A; Oreopoulos DG
    Int Urol Nephrol; 2001; 32(3):463-7. PubMed ID: 11583372
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chloramphenicol sodium succinate kinetics in critically ill patients.
    Slaughter RL; Pieper JA; Cerra B; Brodsky B; Koup JR
    Clin Pharmacol Ther; 1980 Jul; 28(1):69-77. PubMed ID: 7389257
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A method for determining the pharmacokinetics of endogenous creatinine without exogenous creatinine administration.
    Chow MS
    Biopharm Drug Dispos; 1985; 6(2):201-8. PubMed ID: 3890979
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Kinetics of lead following intravenous administration in man.
    Campbell BC; Meredith PA; Moore MR; Watson WS
    Toxicol Lett; 1984 May; 21(2):231-5. PubMed ID: 6719508
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of cefoxitin administered intramuscularly to rabbits with experimentally-induced renal impairment.
    Garcia MJ; Dominguez-Gil AA; Cepeda M; Dominguez-Gil A
    Biopharm Drug Dispos; 1981; 2(3):205-13. PubMed ID: 7295878
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chelation in metal intoxication XXVI : Influence of thiamine on the therapeutic efficacy of calcium disodium edetate in lead intoxication.
    Kachru DN; Khandelwal S; Tandon SK
    Biol Trace Elem Res; 1987 Oct; 14(1-2):79-86. PubMed ID: 24254761
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lead levels in 24-h urine in Japanese adults.
    Jin YP; Kobayashi E; Nogawa K; Kido T; Suwazono Y; Sakurada I; Yin KO; Nakagawa H; Tsuritani I
    Toxicol Lett; 1997 Aug; 92(3):173-8. PubMed ID: 9334827
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Determination by ICP-MS and multivariate data analysis of elemental urine excretion profile during the EDTA chelation therapy: A case study.
    Robotti E; Quasso F; Manfredi M; Gosetti F; Mazzucco E; Isidoro C; Marengo E
    J Trace Elem Med Biol; 2020 Dec; 62():126608. PubMed ID: 32853885
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of calcium disodium versenate (CaNa2EDTA) chelation in moderate childhood lead poisoning.
    Markowitz ME; Bijur PE; Ruff H; Rosen JF
    Pediatrics; 1993 Aug; 92(2):265-71. PubMed ID: 8337028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of lead and arsenic poisoning in anuric patients - a case report and narrative review of the literature.
    Hsiao CY; Gresham C; Marshall MR
    BMC Nephrol; 2019 Oct; 20(1):374. PubMed ID: 31623560
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chelation for autism spectrum disorder (ASD).
    James S; Stevenson SW; Silove N; Williams K
    Cochrane Database Syst Rev; 2015 May; 5(5):CD010766. PubMed ID: 26114777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.